Skip to main content
Elsevier

Drug Discovery Targeting Drug-Resistant Bacteria

  • 1st Edition - May 15, 2020
  • Latest edition
  • Editors: Prashant Kesharwani, Sidharth Chopra, Arunava Dasgupta
  • Language: English

Drug Discovery Targeting Drug-Resistant Bacteria explores the status and possible future of developments in fighting drug-resistant bacteria. The book covers the majority of microb… Read more

End of Summer Sale

Save up to 30% off

Bright savings for research, study, and discovery

Shop the summer sale

Description

Drug Discovery Targeting Drug-Resistant Bacteria explores the status and possible future of developments in fighting drug-resistant bacteria. The book covers the majority of microbial diseases and the drugs targeting them. In addition, it discusses the potential targeting strategies and innovative approaches to address drug resistance. It brings together academic and industrial experts working on discovering and developing drugs targeting drug-resistant (DR) bacterial pathogens. New drugs active against drug-resistant pathogens are discussed, along with new strategies being used to discover molecules acting via new modes of action. In addition, alternative therapies such as peptides and phages are included.

Pharmaceutical scientists, microbiologists, medical professionals, pathologists, researchers in the field of drug discovery, infectious diseases and microbial drug discovery both in academia and in industrial settings will find this book helpful.

Key features

  • Written by scientists with extensive industrial experience in drug discovery
  • Provides a balanced view of the field, including its challenges and future directions
  • Includes a special chapter on the identification and development of drugs against pathogens which exhibit the potential to be used as weapons of war

Readership

Research scientists and industry professionals in pharmaceutical science, biomedicine, microbiology, and biotechnology who are working on technological advancement in designing targeted therapies and drug delivery systems

Table of contents

1. What are drugs and why are they required?2. Drugs against gram-negative bacteria3. Drugs targeting gram-positive bacteria4. Drug repurposing against bacteria5. Drugs against M. tuberculosis6. Drugs against TB and Bioweapons7. New approaches to drug discovery: Peptides/quorum sensing/virulence8. New strategies and targets for antibacterial discovery9. Targeting efflux pumps for AMR10. Discovering antibiotics from Phages11. Drugs against non-tuberculous mycobacteria

Review quotes

"This book provides quality information and is a good educational tool."—Doody

Product details

  • Edition: 1
  • Latest edition
  • Published: May 15, 2020
  • Language: English

About the editors

PK

Prashant Kesharwani

Dr. Prashant Kesharwani is an Assistant Professor of Pharmaceutics at Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, India. His work focuses on translational nanomedicine, polymeric biomaterials, targeted drug delivery, nanoengineered drug delivery systems, and translational pharmaceutical research. He has contributed extensively to the scientific literature and has served as an editor of scholarly books. Dr. Kesharwani has received research funding from national agencies and has been recognized with awards and fellowships for his contributions to the field. His research interests include nanomedicine, targeted and stimuli-responsive drug delivery, polymeric nanocarriers, and related pharmaceutical applications. He is actively involved in scientific research, academic mentoring, and scholarly publishing.

Affiliations and expertise
Dr. Harisingh Gour Vishwavidyalaya University, India

SC

Sidharth Chopra

Dr. Sidharth Chopra is a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~35 international publications in well reputed journals. One of his article is published in Bioresource technology 77 (3), 215-227 with 999 citations and he has extensively worked on discovery and development of NCE against ESKAPE, mycobacterial infections as well as biothreat pathogens.
Affiliations and expertise
Senior Scientist, Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India

AD

Arunava Dasgupta

Dr. Arunava Dasgupta a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~20 international publications in well reputed journals. He has extensively worked on discovery and development of NCE against mycobacterial infections as well as understanding hostpathogen interaction.
Affiliations and expertise
Senior Scientist, Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India

View book on ScienceDirect

Read Drug Discovery Targeting Drug-Resistant Bacteria on ScienceDirect